Introduction
Severe aplastic anemia (SAA) is defined by a marrow cellularity of o25% and two of the following: a neutrophil count o0.5 Â 10 9 /l; plts o 20 Â 10 9 /l and a reticulocyte count of o20 Â 10 9 /l (SAA working party European Group for Blood and Marrow Transplantation (EBMT) consensus conference). 1 The incidence of SAA varies worldwide from 1.5 to 7.8 per million per year. 2 The pathobiology of SAA is believed to be driven by an abnormal expansion of T lymphocytes that directly affect the hematopoietic stem cells, leading to their destruction or to clonal abnormalities, such as paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome 2 in most cases, however the etiology remains unknown and the disease is referred to as idiopathic acquired aplastic anemia.
The treatment of SAA depends on the severity of the aplasia and the patient's age. In patients o40 years of age with an HLA matched sibling donor, hematopoietic SCT (HSCT) is the treatment of choice. 3, 4 The aim of HSCT in SAA is the establishment of complete donor hematopoiesis. 5 The chimeric status of the recipient after HSCT is established using informative markers, which vary from blood group analysis and karyotyping to variable number tandem repeat and STR over the last 30 years. 6 Recovery of host hematopoiesis with the recovery of peripheral blood counts, autologous recovery (AR), may occur after HSCT. AR after HSCT for SAA, can only be determined if sequential chimerism studies are undertaken. AR differs from graft rejection, as in the former there is complete recovery of peripheral blood counts of recipient origin and in the latter pancytopenia occurs most probably reflecting 'disease relapse'. Graft rejection has a poor outcome despite treatment with a second HSCT, immunosupression or donor lymphocyte infusion. 7 Autologous recovery was first reported by Thomas et al. 8 in 1976 9 and subsequently Storb et al. 10 reported one AR patient with long-term survival in a cohort of patients multiply transfused and treated for second HSCT because of SAA relapse (graft rejection). The authors suggested that the second conditioning regimen with anti-thymocyte globulin (ATG) and CY may have enhanced immunosuppression, thereby favoring AR. 10 The reason why some patients develop AR after HSCT remains unclear. A better comprehension of this phenomenon may help to unravel the pathobiology of SAA. We present a large retrospective study on AR cases reported to the EBMT on behalf of the SAA working party.
Patients and methods
The EBMT maintains a database, wherein all centers report consecutive transplant patients. Centers carrying out transplantation for SAA were contacted to participate in this study. Participating centers (n ¼ 57) reported all cases with AR. Patients with graft failure (GF) and without AR, as well as patients without AR and without GF transplanted concurrently in the same centers served as comparison groups. AR patients were reported from 26 centers, GF patients were observed in 49 centers. All consecutive patients from 57 centers were used to calculate incidence. Centers transplanted a median of 13 (1-130) patients. Median follow up of surviving patients was 6.3 (1-34) years.
Definitions
This study included all patients undergoing allogeneic HSCT for SAA reported to the EBMT from participating centers between 1973 and 2005. A total of 57 EBMT centers participated in this study; AR was reported from 26 centers.
Autologous recovery was defined as the recovery of recipient chimerism (with recipient cell percentage close to 100%) proven by any available technology, be it variable number tandem repeat, STR, cytogenetics or blood group serology, with the recovery of blood counts and transfusion independence.
Patients in the AR group included patients who developed AR and remained in remission, and patients with AR who subsequently relapsed. Patients in the GF group included patients who never engrafted, as well as patients who engrafted, but developed late GF. Patients with stable engraftment constitute the comparison group.
Statistical analysis
Variables analyzed included patient and donor gender; patient age; patient-donor gender match; time interval from diagnosis to transplant, donor type, in months from HSCT to AR development; stem-cell source; donor type; conditioning regimen; CMV status; ABO matching; GvHD prophylaxis; and the occurrence of acute (proportion of patients surviving 421 days with grade II-IV GvHD) and chronic GvHD (proportion of patients with any grade chronic GvHD surviving 4100 days).
The Kaplan-Meier estimator, cumulative incidence, Fisher's exact test, the Mann-Whitney U test, the log-rank test, w 2 -test and regression analysis were used where appropriate. Statistical significance was defined as P-value o0.05.
Results
In all, 45 patients with AR were included in this study, 136 patients with GF (primary non-engraftment in 116 and late GF in 20) and 1205 patients with stable engraftment reported by 26, 48 and 57 centers.
Patients in the three groups differed as shown in Table 1 . Patients in the AR and GF were slightly older and had more frequently a longer time interval between diagnosis and transplant, suggesting a higher number of previous transfusions. There were slightly more male donors for female recipients in the AR group (36 vs 20%) vs controls, but this and donor type (unrelated donors slightly more frequent in AR and GF patients) was not statistically significant. Minor ABO mismatch was more frequent in AR and GF patients as compared with control patients, but data is only available for a minority of patients. Patients with AR were more frequently conditioned with regimens containing BU and Cy þ ATG than irradiation or Fludarabine. AR and GF patients received GvHD prophylaxis using T-cell depletion more frequently than controls. Of the 45 patients with AR, there were 40 patients with continuous remission and 5 with subsequent relapse.
In AR patients, the last recorded blood count at follow up was: Hb median 14.0 g/100 ml (range 8.4-17.1); neutrophils median 2.62 Â 10 9 /l (range 1.1-5.0); plts median 167 Â 10 9 /l (range 86-294 Â 10 9 /l). The cumulative incidence of AR was 4.2% (95% confidence interval (CI) 3.1-5.6) using death from all causes as a competing event. Median time to AR onset was 97 days with a range of 30-2331 days for patients with available data. A precise date of onset of AR could not be determined in 30 patients as data on serial-chimerism measurements were lacking. The type of BM donor (sibling or MUD) did not influence the incidence of AR. The identification of AR cases has increased over time. A significant clustering of AR cases between 1991 and 2004 was found. In all, 41 cases of AR were reported when approximately 20 would have been expected (P ¼ 0.001).
Overall survival at 10 years of follow up for AR patients was 84% (95%CI ¼ 83-100%). Survival of patients with full donor chimerism was 74% (95% CI ¼ 71-77), whereas patients with GF had an OS of 16% (95% CI ¼ 9-23%; P ¼ 0.0001) (Figure 1 ). Seven AR patients died. Causes of death were recurrence of aplasia, that is, disease relapse in four after initial AR and infection in three. Of the seven deaths, five had previous relapse of SAA.
Discussion
Hematopoietic SCT for SAA is the treatment of choice for younger patients with a sibling donor. 11 Engraftment is monitored by sequential chimerism analyses. Graft failure is a well-known complication, however intermediate stages of chimerism are also found. 12 For instance, mixed chimerism may be detected before engraftment. Mixed chimerism may evolve into transient mixed chimerism, progressive mixed chimerism with fluctuation of recipient cells between 410% or o15% or stable mixed chimerism with o5% fluctuation of recipient cells. 13 Progressive mixed chimerism is associated with GF, 14 whereas stable mixed chimerism is associated with a good prognosis and low risk of GvHD. 12 Autologous reconstitution defines the situation wherein complete autologous recovery occurs, which is detected by chimerism analysis.
This study establishes AR incidence in transplanted SAA patients, showing an incidence of 4.2% (3.1-5.6). When comparing patients with AR to patients with GF and patients with stable engraftment, it becomes apparent that AR and GF may share risk factors, such as slightly older age, more T-cell depleted transplants, a longer time interval between diagnosis and transplantation and, thus, more sensitization due to transfusions.
Other factors associated with AR are more difficult to interpret. AR patients received peripheral blood transplants more frequently than controls, possibly reflecting the fact that AR is diagnosed more frequently in recent than in dated cohorts. AR was associated with some conditioning regimens, more frequently with Cy þ ATG. Increased immunosuppression in the form of ATG was instituted into SAA conditioning regimens to prevent graft rejection (failure). 10 We are not able to explain these findings, however, it is tempting to speculate that ATG based conditioning may favor AR because ATG may contribute to eradicate abnormal T-lymphocytic clones, sustaining SAA. Conversely, irradiation regimens and regimens containing Fludarabine may be more immunosuppressive and promote engraftment. Bacigalupo et al. 15 have reported a high incidence of AR when reduced intensity conditioning was used for SAA patients undergoing HSCT from matched unrelated donors, but no long-term survival data is available. Why is AR associated with the use of BU is not easily determined?
Our finding of an increased incidence of AR (P ¼ 0.01) since 1991 may reflect a real increase or the more frequent detection of autologous reconstitution because of progress in the technology to detect chimerism. This increase in AR occurrence should, therefore, be interpreted with great caution.
Even though the difference was not significant it is of interest that there were more male donors for female recipients in the AR group (36%) vs the control groups. This may imply an H-Y effect that acts sufficiently slowly to result in GF at a time when autologous reconstitution has occurred. 16 The presence of GvHD in AR and in GF patients is somewhat surprising, but may be explained by transient GvHD followed by either GF or AR and also by clinical manifestations such as skin rash and diarrhea being erroneously recorded as GvHD.
Survival of patients with AR is shown in Figure 1 and compared to patients with GF and with stable engraftment. AR patients appear to have a prognosis that is, at least, equivalent to patients with successful engraftment and HSCT follow up in years Cum survival Figure 1 Shows cumulative survival of patients demonstrating autologous recovery (AR) (OS ¼ 84%, ± 95% confidence interval (CI)) after hematopoietic SCT (HSCT) compared with patients with donor chimerism (OS ¼ 74%, ± 95% CI) and graft failure (OS ¼ 16%, ± 95% CI) at 10 years of follow up (P ¼ 0.000).
much better than patients with graft failure. This has to be interpreted carefully, as we could not perform a proper landmark analysis given the fact that we lacked data on the date of AR in a substantial number of patients. The control group may have included additional patients with undiagnosed AR. We therefore conducted a separate analysis on patients with stable engraftment and serial chimerism showing full donor engraftment. Among these patients (n ¼ 465) with a mean number of chimerism analyses of 2.7 survival at 10 years was 94 (91-97)%. We do not show these results as these patients reflect a selected group surviving long enough to allow for serial chimerism analyses to be carried out. Of the 45 patients with AR 7 who died, the cause of death was either a relapse of SAA or infectious complications. Graft failure is well documented after HSCT for SAA. Previous transfusions have been shown to influence this incidence. 5 These patients experience pancytopenia, which is either persistent or becomes persistent after a brief period of recovery of peripheral blood counts following HSCT. The outcome of patients with graft rejection (failure) is poor but may have improved over time. 17 These patients frequently require a second HSCT and commonly experience rejection of the second graft from the original donor. 18 In this study 13% had graft failure, which is in accordance with previous reports 19 and reflects a population with 25% of unrelated and mismatched related donors.
This study has several limitations. It is retrospective and extends over many years. Technology to determine chimerism has changed. We included all the patients identified as having AR irrespective of whether they had serial chimerism tests done or not. We therefore lack data on the exact date of AR in 30 out of 45 patients. Furthermore, we may underestimate the AR incidence as detailed data have been recorded for AR patients, whereas the control patients were retrieved from the EBMT database. This also explains that there were more missing data in the two control groups.
In conclusion, AR remains an enigmatic event, and may be seen as a consequence of immunosuppression with reemergence of host hematopoiesis, which sustains normal peripheral blood counts in the long term. Patient outcome is satisfactory and additional prespective studies are warranted to confirm these findings.
